Objectives: The objectives of this study were to compare short-and intermediate-term clinical outcomes, procedural complications, TAVR prosthesis hemodynamics, and paravalvular leak (PVL) in stentless and stented groups.
stented valves are mounted on structure support such as a stent or frame. 1 Stented valves provided easier implantation, however, sacrificed orifice area and increased stress at the stent attachment sites. 2 The stentless bioprosthetic valve has been reported to provide better hemodynamic properties compared with stented bioprosthetic valves with less turbulent flow and larger effective orifice area, which reduces the risk of patient-prosthesis mismatch. However, some of the disadvantages of stentless aortic bioprosthetic valves include association with significant calcification of the aortic root, therefore, making reoperation more difficult. In the past, the standard of care for bioprosthetic aortic valve failure has been redo AVR surgery. Redo surgery is associated with increased risk of morbidity and mortality of 3-7%, rising to 30% in high risk patients. 3 With the introduction of transcatheter aortic valve replacement (TAVR), patients with increased surgical risks now have a promising alternative to surgical redo AVR, referred to as valve-in-valve (ViV)
implantation. [4] [5] [6] Stentless bioprosthetic valves make ViV implantation especially challenging given the lack of a frame or structural support to anchor the new transcatheter aortic valve, differences in modes of index valve failure, as well as lack of radiographic markers to help with proper positioning. 1 
| METHODS
Our study retrospectively investigated 40 consecutive patients who underwent ViV implantation with previous surgical AVRs at Wake Forest Baptist Medical Center from October 2014 to September 2017.
Patients were identified using electronic medical record system with CPT diagnosis codes in patients that underwent past-SAVR and received ViV-TAVR and cross confirmed with internal TAVR database.
Baseline patient demographics, comorbidities, post-ViV complications, and valve hemodynamics were followed longitudinally at 1-, 6-, and 12-month follow-ups with repeat echocardiograms, clinic visits, and phone calls. Follow-ups were displayed as percentages per group at 1-, 6-, and 12-month intervals. All patients provided written informed consent for the procedure and data collection according to the policy of the Institutional Review Board of Wake Forest Baptist Medical Center. 
| Pre-procedural protocol

| Study endpoints
The primary endpoint of our study was all-cause mortality at 1 year.
Secondary endpoints included stroke, vascular complications, valve embolization and migration, device success, procedural success, valve hemodynamics, permanent pacemaker implantation, and hospitalization rates. The Valve Academic Research Consortium 2 (VARC-2) criteria were used to major and minor vascular complications, myocardial infarction, arrhythmia, cerebrovascular events, and death. 6 Device success was defined as successful vascular access, delivery and deployment of the device and successful retrieval of the delivery system, correct position of the device in the proper anatomical location, intended performance of the prosthetic heart valve (aortic valve area > 1.2 cm 2 and mean aortic valve gradient <20 mmHg or peak velocity < 3 m/s, without moderate or severe prosthetic valve AR), and only one valve implanted in the proper anatomical location according to VARC criteria. 7 Procedural success was defined as final device in proper anatomic position with satisfactory hemodynamics according to VARC-2 criteria, patient survival within 72 hr post-procedure, and no conversion to surgical operation. 
| Statistical analysis
| Procedural outcomes
Complete procedural data are listed in Table 2 . Aortic regurgitation as an indication for ViV TAVR was more prevalent in the stentless (78%) versus the stented (25%, P < 0.05) group. Aortic stenosis was more common in the stented (75%) than in the stentless (28%, P < 0.05) group. The most commonly used transcatheter heart valve (THV) was in the stented group. The other less commonly utilized approaches included subclavian and transapical as noted in Table 2 .
Complete procedural complications are listed in to open heart surgery.
| Early and late outcomes
One-month follow-up outcomes are listed in Table 4 . Follow-up rates for stentless and stented groups for 1, 6, and 12 months were the following: 87.5% (28/32) and 100% (8/8), 50% (16/32) and 50% (4/8),
and 50% (16/32) and 62.5% (5/8), respectively. There were patients that were lost to follow-up and some patients had missing data, therefore were excluded. Stroke rates were similar in both groups, 3%
(1/31) and 0% (0/8) in the stentless and stented groups, respectively.
New permanent pacemaker implantation was more prevalent in the stentless group (6%) compared to the stented group (0%). The stentless group had 6% (2/31) of patients that had a major vascular complication compared to none in the stented group. At 6-and 12-month The available 1-year all-cause mortality data showed that neither the stentless or stented group had deaths within this time frame (0%, 0/25 versus 0%, 0/5, respectively). All-cause mortality for 30 days, 6 months, and 1 year are shown in Table 5 . There was no significant difference in re-hospitalization rates between the two groups. Re-hospitalization data for 30 days, 6 months, and 1 year are shown in Table 5 . Stroke rates were also similar between the two groups (Table 5 ).
| Echocardiographic data and outcomes
Complete longitudinal echocardiographic data for baseline and 1-, 6-, and 12-month follow-ups are listed in Table 6 . Baseline ejection fraction (EF) was similar in both the stentless and stented groups (52.2 AE 11.9%
and 55.6 AE 9.4%, respectively). Etiologies for valve failure were different in stentless versus stented groups with 78% (25/32) of stentless and 25% At 30-day follow-up, the stentless group had a larger aortic valve area compared to the stented group (1.66 AE 0.68 mm versus 1.11 AE 0.48 mm [P < 0.05], respectively). The aortic valve mean gradient in the stentless and stented groups was 12.3 AE 6.3 mmHg versus 22.6 AE 8.5 mmHg (P < 0.005), respectively. The aortic peak gradient in the stentless and stented groups was 21.8 AE 10.6 mmHg versus 43.1 AE 17.7 mmHg (P < 0.01), respectively. At 30 days, 68% in the stentless and 25% in the stented groups had trace to mild paravalvular leak (PVL) (P < 0.05), however, no significant difference in moderate to severe PVL. The stentless group had a significantly lower EF compared to the stented group (47.0 AE 14.8% versus 56.9 AE 7.5%, P < 0.05). There was no significant increase in EF change from pre-discharge in both groups (Figure 1 ).
At 6 months, the aortic valve area was similar in both groups (Table 4 ). The stentless group had a significant increase in EF from 1-month follow-up (P < 0.005), whereas the stented group remained similar (P = 0.75) (Figure 1 ). The aortic valve mean gradient remained lower in the stentless group compared to the stented group (9.8 AE 5.1 mmHg versus 24.0 AE 11.3 mmHg, respectively [P < 0.05]). At 6 months, 0% in both the stentless and stented groups had moderate to severe PVL.
At 12 months, the EF was similar in both groups and no significant change in EF from 6-month follow-up. The aortic valve area of the stentless and stented groups was found to be similar (1.76 AE 0.57 mm versus 1.53 AE 1.03 mm, respectively). The aortic valve mean gradient was found to be significantly lower in the stentless compared to the stented group (9.5 AE 4.4 mmHg versus 22.5 AE 11.2 mmHg, P < 0.01, respectively).
There were no significant differences in PVL severity. Comparisons of mean gradient and aortic valve area between both groups over a 12-month period are shown in Figure 2 . Comparisons of aortic PVL severity between both groups over a 12-month period are shown in Figure 3 .
| DISCUSSION
The current study has demonstrated that ViV in stentless surgical bioprosthetic valve is feasible and safe with comparable clinical outcomes as in stented surgical bioprosthetic valve. Hemodynamics of ViV in the stentless group were superior with a larger effective orifice area There were similar 30-day mortality (10% for both groups, P = 1.0)
and one-year survival (83.1 AE 7.7% versus 81.5 AE 7.5%, P = 0.76).
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Our study has demonstrated comparable clinical outcomes of ViV in stentless group as compared to stented group. In the Global Valve-inValve Registry, high post-procedural gradients were common at 28%.
Interestingly, we have observed superior hemodynamics of ViV in the stentless as compared to the stented group. The stentless group had a larger effective orifice area at 30 days and lower mean aortic gradient throughout 1-year follow-ups. It is easily understandable that the absence of a stent rendered a larger effective orifice area of prosthesis and reduction in the mean aortic gradient. 18 The stentless had significantly more overall PVL (i.e., trivialsevere) than the stented group at 1 month (P < 0.05), however, the PVL improved at 6-month follow-up and remained stable in the stent- Stentless bioprosthetic valves make ViV implantation especially challenging given the lack of a frame or structural support to anchor the TAVR, as well as lack of radiographic markers to help with proper positioning. Our study has confirmed such concerns. In patients with stentless valve and primary mode of aortic insufficiency, identifying appropriate aortic annulus is challenging. We have used a multimodality imaging approach to assist in positioning the TAVR device. We also used multiple Pigtail catheters that were placed in the right and non-coronary cuspids to assist in positioning. It proved to be less of a problem in patients with aortic stenosis as the primary mode of failure. Positioning was similar as in the native valve TAVR procedure.
More TAVR migration and embolization were present in the stentless group, which were either secondary to utilizing a smaller size THV or improper placement (placement is usually too low). To help reduce this complication, it is essential to select an appropriately sized THV by utilizing the true internal diameter of the prior surgical aortic valve as a guide and ideal placement. 18 THV oversizing is commonly recommended to prevent complications of valve migration, embolization, and malpositioning. 18, 19 However, one must exercise caution given the risk of coronary obstruction with oversized valve implantation. In particular, stentless bioprosthetic valves will have a smaller gap between the THV and the coronary ostia given the free-style suturing nature of the prior surgically placed aortic valve. 20 At the first deployment, if the device had a tendency to migrate distally, we adopted a strategy to deploy valve deep in the ventricle using the waist of the Medtronic CoreValve as an anchor to secure the second THV in a proper position. In our limited experience and follow up, we have not observed adverse effects with the first THV deployed relatively deep in the ventricle. In patients with aortic regurgitation, the hemodynamics tended to be stable as they tolerated the first THV regurgitation well as second THV was prepared. However, in patients with aortic stenosis, the hemodynamics may deteriorate quickly. Therefore, it is critical to have the second THV loaded and ready to deploy before releasing the first valve. 
| Study limitations
This was a retrospective observational study of a single center's experience of comparing ViV TAVR in failed stentless versus stented bioprosthetic aortic valves. Our study was limited by the small sample size in both groups, particularly in the stented group, as well as being limited to a single center's experience. However, one of the study's strengths is the relatively larger number of stentless cases compared to what is currently available in the literature. Another limitation is that patients in those groups were not completely similar, more specifically in regards to primary mode of valve failure, therefore, must also consider these differences during the Heart Team evaluation and local expertise. Future and larger prospective multi-center studies are needed to further validate our current findings. 
